Homepage Bottom Left
-
Management of comorbidities in bleeding disorders
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...
-
Substitution therapy
Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...
-
Plasma Saves Lives: Addressing the COVID-19 Pandemic
The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the...
-
Hemophilia Research Million Dollar Club – Report from the chair
The Hemophilia Research Grants Review Committee, under the chairmanship of Dr. Manuel Carcao, met earlier this year and announced the 2020 grant recipients for the...
-
Update of Phase 2b trial of UniQure’s AMT-061 gene therapy trial in hemophilia B
Dr. Steven Pipe, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program in Ann Arbor Michigan, presented an update at the World Federation of...